Andere Sprachen CG Oncology, Inc.

Aktien

A3EKLQ

US1569441009

CGON

Realtime-Estimate Cboe BZX Andere Börsenplätze 21:00:46 28.05.2024			% 5 Tage	% 1. Jan.
32,19 ^USD	-1,59 %		+11,15 %	0,00 %

24.05.	Sektor-Update: Aktien des Gesundheitswesens am Freitagnachmittag schwächer	MT
24.05.	CG Oncology-Aktien steigen, nachdem die potenzielle Kombinationstherapie für Blasenkrebs den primären Endpunkt der Phase 2 erreicht hat	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Sector Update: Health Care Stocks Softer in Friday Afternoon Trading	24.05.
CG Oncology Shares Jump After Potential Combination Therapy for Bladder Cancer Meets Phase 2 Primary Endpoint	24.05.
CG Oncology Says Potential Combination Therapy for Bladder Cancer Meets Phase 2 Primary Endpoint	24.05.
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting	24.05.
CG Oncology, Inc. to Present Positive Final Results from Phase 2 Core-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC At Asco 2024 Annual Meeting	24.05.
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates	09.05.
CG Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
CG Oncology, Inc. - Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	06.05.
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	03.05.
CG Oncology, Inc. Announces Data from the Phase 3 BOND-003 Study Evaluating the Efficacy and Safety of Cretostimogene Monotherapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette Guerin	03.05.
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024	26.04.
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024	24.04.
PACS Group to raise $450 mln in US IPO at over $3 bln valuation	11.04.
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting	28.03.
CG Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26.03.
CG Oncology, Inc.(NasdaqGS:CGON) added to S&P TMI Index	18.03.
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer	27.02.
Moderna, Bayer-backed Metagenomi stock drops 32% on Nasdaq debut	09.02.
Fractyl Health valued at $654.6 mln in tepid debut	02.02.
Fractyl Health prices US IPO below range to raise $110 mln	02.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen CG Oncology, Inc.

Aktien

A3EKLQ

US1569441009

CGON

Andere Sprachen

Filter